Deadly Arrhythmias Less of a Risk for HF Patients on Dapagliflozin
An SGLT2 inhibitor seemed to offer protection from reduced ventricular arrhythmias in heart failure patients, according to a post hoc analysis of DAPA-HF. In that trial, the cohort randomized to dapagliflozin (Farxiga) had a reduced first occurrence of any ventricular arrhythmia, resuscitated cardiac arrest, or sudden death (5.9% vs 7.4% for placebo group; HR 0.79, […]